On July 27, 2023, Pfizer Inc. announced that in consideration of planned future investments in Oncology, including the proposed acquisition of Seagen Inc., it is restructuring its Research and Development organization with Oncology as a stand-alone unit. Effective immediately, Dr. Chris Boshoff, currently Chief Development Officer ? Oncology, will become Chief Oncology Research and Development Officer, Executive Vice President, and the remainder of early and late-stage development will be consolidated and led by Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research and Development.

As a result of this reorganization, the role held by Dr. William Pao, Chief Development Officer, Executive Vice President, is being eliminated and he will leave the Company effective August 15, 2023. This action by the Company will constitute an involuntary termination without cause.